Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertension

Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

GALT

0.00
  • Galectin Therapeutics outlined plans to file a Phase 3 protocol in Q3 2026 for belapectin in MASH cirrhosis with portal hypertension.
  • NAVIGATE Phase 2b/3 trial completed; per-protocol varices incidence fell to 11.3% on belapectin 2 mg vs 22.3% on placebo (p=0.04).
  • Intent-to-treat composite primary endpoint missed statistical significance (p=0.13 for 2 mg; p=0.55 for 4 mg).
  • Pipeline focus remains belapectin, a galectin-3 inhibitor with Fast Track status, targeting portal hypertension where no approved reversal therapies exist.
  • Oncology program highlighted belapectin with Keytruda; clinical activity cited in checkpoint combinations, with FDA clearance to proceed in head and neck cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.